Tag: WJMSCs

Comparison efficacy of ESWT and Wharton’s jelly mesenchymal stem cell in early osteoarthritis of rat knee

This 2019 preclinical study evaluated the therapeutic effects of extracorporeal shockwave therapy (ESWT), Wharton’s jelly-derived mesenchymal stem cells (WJMSCs), and their combination in a rat model of early knee osteoarthritis (KOA). All treatment modalities significantly improved cartilage integrity and subchondral bone remodeling, as evidenced by pathological assessments, micro-CT, and immunohistochemical

Read More »

Shockwave Therapy Combined with Autologous Adipose-Derived Mesenchymal Stem Cells Is Better than with Human Umbilical Cord Wharton’s Jelly-Derived Mesenchymal Stem Cells on Knee Osteoarthritis

This 2020 preclinical study evaluated the efficacy of combining extracorporeal shockwave therapy (ESWT) with either autologous adipose-derived mesenchymal stem cells (ADMSCs) or human umbilical cord Wharton’s jelly-derived mesenchymal stem cells (WJMSCs) in treating early-stage knee osteoarthritis (KOA) in a rat model. The ESWT+ADMSCs group demonstrated superior outcomes, including increased trabecular

Read More »